Related Experiment Video
Updated: May 4, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Mitigation of postischemic cardiac contractile dysfunction by CaMKII inhibition: effects on programmed necrotic and
Adrian Szobi1, Tomas Rajtik, Slavka Carnicka
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Odbojarov 10, 83232, Bratislava, Slovak Republic.
Abstract:
While Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) has been suggested to be an important protein regulating heart function upon ischemia/reperfusion (I/R), the mechanisms responsible are not fully known. Furthermore, it is not known whether CaMKII activation can modulate necroptosis, a recently described form of programmed cell death. In order to investigate these issues, Langendroff-perfused rat hearts were subjected to global ischemia and reperfusion, and CaMKII inhibition was achieved by adding the CaMKII inhibitor KN-93 (0.5 μmol/dm(3)) to the perfusion solution before the induction of ischemia. Immunoblotting was used to detect changes in expression of proteins modulating both necroptotic and apoptotic cell death. CaMKII inhibition normalized I/R induced increases in expression of necroptotic RIP1 and caspase-8 along with proteins of the intrinsic apoptotic pathway, namely cytochrome c and caspase-9. In addition, it increased the Bcl-2/Bax ratio and reduced caspase-3 and cleaved PARP1 content suggesting reduction of cell death. These changes coexisted with improvement of postischemic contractile function. On the other hand, there was no correlation between levels of pT287-CaMKIIδ and LVDP recovery after I/R. These results demonstrate for the first time that CaMKII inhibition may mitigate cardiac contractile dysfunction, at least partially, by limiting the contents of not only apoptotic, but also necroptotic proteins. Phosphorylation of CaMKII seems unlikely to determine the degree of postischemic recovery of contractile function.
Insights
Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibition protects heart function after ischemia/reperfusion by reducing both apoptotic and necroptotic cell death proteins. This suggests CaMKII plays a key role in cardiac injury.
Area of Science:
- Cardiology
- Molecular Biology
- Cell Death Research
Background:
- Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is implicated in cardiac function regulation during ischemia/reperfusion (I/R).
- The precise mechanisms and CaMKII's role in necroptosis, a form of programmed cell death, remain unclear.
Purpose of the Study:
- To investigate the role of CaMKII in cardiac I/R injury.
- To determine if CaMKII inhibition affects necroptosis and apoptotic pathways.
- To assess the impact of CaMKII inhibition on post-ischemic cardiac function.
Main Methods:
- Langendorff-perfused rat hearts subjected to global ischemia and reperfusion.
- CaMKII inhibition using KN-93.
- Immunoblotting to analyze protein expression related to apoptosis and necroptosis.
Main Results:
- CaMKII inhibition normalized I/R-induced increases in RIP1, caspase-8, cytochrome c, and caspase-9.
- Inhibition increased the Bcl-2/Bax ratio and reduced caspase-3 and cleaved PARP1 levels.
- CaMKII inhibition improved post-ischemic cardiac contractile function.
- No correlation was found between pT287-CaMKIIδ levels and left ventricular developed pressure (LVDP) recovery.
Conclusions:
- CaMKII inhibition mitigates cardiac dysfunction following I/R by reducing both apoptotic and necroptotic protein levels.
- CaMKII appears to be a significant modulator of cell death pathways in cardiac I/R injury.
- Phosphorylation of CaMKII may not directly correlate with the degree of post-ischemic contractile function recovery.
Related Concept Videos
Cellular Injury IV: Necrosis
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

